Human immunodeficiency virus type 1 Trans-activator of transcription protein (Tat)

The Human immunodeficiency virus type 1 (HIV-1) Trans-activator of transcription (Tat) protein is a critical regulatory protein required for efficient viral gene expression and replication (UniProt: P04608). Unlike most viral proteins, Tat is actively secreted by infected cells and can be taken up by neighboring uninfected cells, where it exerts various pathological effects, including immune suppression and neurotoxicity (Ensoli et al., 2021, Nature Communications). As a therapeutic target, Tat is unique because it is expressed early in the viral life cycle, making it an ideal candidate for vaccine-induced immune responses. Therapeutic vaccines targeting Tat aim to elicit high-titer neutralizing antibodies to block extracellular Tat activity and stimulate CD8+ T-cell responses to destroy cells actively producing the virus (Monini et al., 2018, Expert Review of Vaccines). By neutralizing Tat, these therapies seek to restore immune homeostasis and reduce the latent viral reservoir in HIV-infected individuals on antiretroviral therapy (ART). Clinical studies have demonstrated that Tat-specific immune responses correlate with slower disease progression and improved CD4+ T-cell recovery (Sgadari et al., 2011, PLoS ONE).

Other names

p14HIV-1 TatTrans-activator of transcriptionTat protein

Neutralization of extracellular Tat protein by vaccine-elicited antibodies and elimination of Tat-expressing cells by cytotoxic T lymphocytes.